Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Slideshows|March 15, 2021
10 Facts About Geriatric Pharmacotherapy
Author(s)Sandra Jacobson, MD
It is important to monitor and alter psychotropic medications and dosages in older patients as needed. This slideshow serves as quick reference on the effects of pharmacokinetic and pharmacodynamic changes in the elderly.
Advertisement
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
Check out our pipeline updates from September!
A cross-sector ACNP task force calls for shared standards and shared data to move psychiatry beyond trial-and-error prescribing.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
2
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
3
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
4
From Side Effect to Target: Rethinking Metabolic Dysfunction in Psychiatry
5